Each Donnatal Extentabs tablet contains:
Scopolamine Hydrobromide, USP ................. 0.0195 mg
Each Donnatal Extentabs tablet contains the equivalent of three Donnatal tablets. Extentabs are designed to release the ingredients gradually to provide effects for up to twelve (12) hours.
Inactive Ingredients: Acacia, Acetylated Monoglycerides, Calcium Sulfate, Carnauba Wax, D&C Yellow 10, Edible Ink, FD&C Blue 1, FD&C Blue 2 Aluminum Lake, FD&C Yellow 6, Gelatin, Guar Gum, Magnesium Stearate, Polysorbates, Shellac, Sodium Phosphate, Sucrose, Titanium Dioxide, Wheat Flour, White Wax and other ingredients, one of which is a corn derivative. May include FD&C Red 40 and Yellow 6 Aluminum Lakes.
This drug combination provides natural belladonna alkaloids in a specific, fixed ratio combined with phenobarbital to provide peripheral anticholinergic/antispasmodic action and mild sedation.
Based on a review of this drug by the National Academy of Sciences--National Research Council and/or other information, FDA has classified the following indications as "possibly" effective:
May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS.
Glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic megacolon; myasthenia gravis; hiatal hernia associated with reflux esophagitis.
Donnatal is contraindicated in patients with known hypersensitivity to any of the ingredients. Phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement.
In the presence of a high environmental temperature, heat prostration can occur with belladonna alkaloids (fever and heatstroke due to decreased sweating).
Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.
Donnatal may produce drowsiness or blurred vision. The patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work.
Phenobarbital may decrease the effect of anticoagulants and necessitate larger doses of the anticoagulant for optimal effect. When the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.
Phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs.
Since barbiturates are metabolized in the liver, they should be used with caution and initial doses should be small in patients with hepatic dysfunction.
Use with caution in patients with: autonomic neuropathy, hepatic or renal disease, hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, tachycardia, and hypertension.
Belladonna alkaloids may produce a delay in gastric emptying (antral stasis) which would complicate the management of gastric ulcer.
Theoretically, with overdosage, a curare-like action may occur.
Carcinogenesis, mutagenesis. Long-term studies in animals have not been performed to evaluate carcinogenic potential.
Pregnancy Category C. Animal reproduction studies have not been conducted with Donnatal. It is not known whether Donnatal can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Donnatal should be given to a pregnant woman only if clearly needed.
Nursing mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Donnatal is administered to a nursing mother.
Adverse reactions may include xerostomia; urinary hesitancy and retention; blurred vision; tachycardia; palpitation; mydriasis; cycloplegia; increased ocular tension; loss of taste sense; headache; nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; musculoskeletal pain; severe allergic reaction or drug idiosyncrasies, including anaphylaxis, urticaria and other dermal manifestations; and decreased sweating. Elderly patients may react with symptoms of excitement, agitation, drowsiness, and other untoward manifestations to even small doses of the drug.
Phenobarbital may produce excitement in some patients, rather than a sedative effect. In patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsions.
The dosage of Donnatal Extentabs should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse reactions. The usual dose is one tablet every twelve (12) hours. If indicated, one tablet every eight (8) hours may be given.
The signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils; hot and dry skin, dizziness, dryness of the mouth, difficulty in swallowing, CNS stimulation. Treatment should consist of gastric lavage, emetics, and activated charcoal. If indicated, parenteral cholinergic agents such as physostigmine or bethanechol chloride should be added.
Pale green, coated tablets, monogrammed AHR and Donnatal Extentab in bottles of 100 (NDC 0031-4235-63) and 500 (NDC 0031-4235-70); and Dis-Co® Unit Dose Packs of 100 (NDC 0031-4235-64).
Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F).
Dispense in well-closed, light-resistant container.
A.H. Robins Company
Richmond, VA 23220
CI 4693-1 Issued November 1994